A high-level overview of Protara Therapeutics, Inc. (TARA) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.

2 dagar sedan · Ocugen, Brooklyn ImmunoTherapeutics leads healthcare gainers; Inovio Pharmaceuticals, Protara Therapeutics among major losers Apr. 23, 2021 11:01 AM ET Ocugen, Inc. (OCGN) By: Khyathi Dalal , SA

NEW YORK, May 11, 2020 (GLOBE NEWSWIRE) -- ArTara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company identifying and advancing transformative therapies for people with rare and specialty diseases, today announced that it has changed its name to Protara Therapeutics, Inc., effective immediately. 2020-05-11 · NEW YORK, May 11, 2020 (GLOBE NEWSWIRE) -- ArTara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company identifying and advancing transformative therapies for people with rare and specialty View the real-time TARA price chart on Robinhood and decide if you want to buy or sell commission-free. Change the date range, see whether others are buying or selling, read news, get earnings results, and compare Protara Therapeutics against related stocks people have also bought. 2020-08-11 · Protara Therapeutics, Inc. is a clinical-stage company engages in developing treatments for rare and specialty diseases with significant unmet needs.

$15.11. Now: $15.94 $16.06. 50-Day NEW YORK, April 19, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases NEW YORK, April 23, Apr 23, 2021 (GLOBE NEWSWIRE via COMTEX) -- NEW YORK, April 23, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing NEW YORK, April 19, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced the grants of inducement non-qualified stock options to PROTARA THERAPEUTICS, INC. : News, information and stories for PROTARA THERAPEUTICS, INC. | Nasdaq: TARA | Nasdaq Recent executive movements at Protara Therapeutics. Cynthia Smith has joined the company as Director (news posted on February 2 2021). Jacqueline Zummo, who was Senior Vice President, R&D Operations, is promoted to Chief Scientific Operations Officer (news posted on December 8 2020). Following feedback from the FDA, Protara Therapeutics will complete a confirmatory, large-scale, GMP manufacturing comparability study in 2H 2021 for TARA-002 for Lymphatic Malformations.

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company’s lead p

With this latest performance, TARA shares dropped by -7.58% in over the last four-week period, additionally sinking by -20.66% over the last 6 months – not to mention a rise of 79.22% in the past year of trading. NEW YORK, May 11, 2020 (GLOBE NEWSWIRE) -- ArTara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company identifying and advancing transformative therapies for people with rare and specialty diseases, today announced that it has changed its name to Protara Therapeutics, Inc., effective immediately. 2020-05-11 · NEW YORK, May 11, 2020 (GLOBE NEWSWIRE) -- ArTara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company identifying and advancing transformative therapies for people with rare and specialty View the real-time TARA price chart on Robinhood and decide if you want to buy or sell commission-free. Change the date range, see whether others are buying or selling, read news, get earnings results, and compare Protara Therapeutics against related stocks people have also bought.

2 dagar sedan · Ocugen, Brooklyn ImmunoTherapeutics leads healthcare gainers; Inovio Pharmaceuticals, Protara Therapeutics among major losers Apr. 23, 2021 11:01 AM ET Ocugen, Inc. (OCGN) By: Khyathi Dalal , SA

2021-01-05 2 days ago 2021-04-19 Protara Therapeutics (NASDAQ TARA) News Headlines Today Source: All Sources Trusted Sources MarketBeat.com Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NEW YORK, April 19, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage Protara Therapeutics, Inc. 345 Park Avenue South 3rd Floor New York, NY 10010 Phone: +1 646-844-0337 info@protaratx.com Protara Therapeutics, Inc. 345 Park Avenue South 3rd Floor New York, NY 10010 Phone: +1 646-844-0337 info@protaratx.com Recent executive movements at Protara Therapeutics. Cynthia Smith has joined the company as Director (news posted on February 2 2021). Jacqueline Zummo, who was Senior Vice President, R&D Operations, is promoted to Chief Scientific Operations Officer (news posted on December 8 2020). Barry Flannelly has joined the company as Director (news posted on July 24 2020).

The company can be reached via phone at 646-844-0337 or via email at [email protected] This page was last updated on 4/20/2021 by MarketBeat.com Staff Protara Therapeutics(TARA) appointed 15 years industry veteran Martín Sebastian Olivo, M.D. as Chief Medical Officer NEW YORK, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases 2 dagar sedan · Ocugen, Brooklyn ImmunoTherapeutics leads healthcare gainers; Inovio Pharmaceuticals, Protara Therapeutics among major losers Apr. 23, 2021 11:01 AM ET Ocugen, Inc. (OCGN) By: Khyathi Dalal , SA 2020-10-02 · View the latest Protara Therapeutics Inc. (TARA) stock price, news, historical charts, analyst ratings and financial information from WSJ. 2020-06-02 · NEW YORK, June 02, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a development-stage clinical biopharmaceutical company developing treatments for rare and specialty diseases 2020-10-05 · Protara Therapeutics Inc. [TARA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 7.91. With this latest performance, TARA shares dropped by -7.58% in over the last four-week period, additionally sinking by -20.66% over the last 6 months – not to mention a rise of 79.22% in the past year of trading.
Skolverket pisa resultat

TARA is currently trading at $12.50, down $2.44 or 16.33%, on the Nasdaq. Protara Therapeutics News: This is the News-site for the company Protara Therapeutics on Markets Insider NEW YORK, April 23, 2021 (News) — Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced a path forward related to TARA-002 for the treatment of Lymphatic Malformations (LMs), which are rare malformations of the lymphatic vasculature for which there is Protara Therapeutics (NASDAQ TARA) News Headlines Today Source: All Sources Trusted Sources MarketBeat.com Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Protara Therapeutics, Inc. 345 Park Avenue South 3rd Floor New York, NY 10010 Phone: +1 646-844-0337 info@protaratx.com. About Us; Pipeline; Careers; Investors 2021-04-19 · NEW YORK, April 19, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases Protara Therapeutics, Inc. 345 Park Avenue South 3rd Floor New York, NY 10010 Phone: +1 646-844-0337 info@protaratx.com Recent executive movements at Protara Therapeutics. Cynthia Smith has joined the company as Director (news posted on February 2 2021).

Protara Therapeutics (NASDAQ:TARA) priced its two concurrent but separate underwritten public offerings of 4.6M shares for $16.87/share and 4,148 shares of its non-voting Series 1 Convertible 2021-04-19 2021-04-19 Protara Therapeutics News .
Ett brustet halleluja

NEW YORK, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced the appointment of Cynthia Smith to its Board of Directors. Ms. Smith brings to Protara over 20 years of diverse leadership experience within the healthcare

Dr. Olivo, 45, brings more than 15 years of experience in oncology translational and clinical research and global drug development. PROTARA THERAPEUTICS AKTIE und aktueller Aktienkurs. Nachrichten zur Aktie Protara Therapeutics Inc Registered Shs | A2P4JE | TARA | US74365U1079 Denna sida innehåller de senaste nyheterna om Protara Therapeutics Inc aktien. SEC Filing – Protara Therapeutics, Inc. Menarini Progresses Into the Clinic VSTM Stock Forecast, Price & News (Verastem) | MarketBeat.

Balett termer

Abeona Therapeutics Inc. BlackBerry Ltd · Booking Holdings Inc. O'Reilly Automotive, Inc. News Corporation - Class A · Marvell Technology aTyr Pharma, Inc.

NEW YORK, April 23, 2021 (News) — Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced a path forward related to TARA-002 for the treatment of Lymphatic Malformations (LMs), which are rare malformations of the lymphatic vasculature for which there is Protara Therapeutics News . Follow TARA. 12.28-2.70 (-18.02%) Upgrade to Real-Time Regular Market . Securities Registration: Employee Benefit Plan (s-8) March 11 2021 - 07:36AM Edgar (US Regulatory) As filed with the Securities and Exchange Commission on March 11, 2021.

Protara Therapeutics news and TARA price. Free real-time prices, trades, and chat.

Free real-time prices, trades, and chat. PROTARA THERAPEUTICS, INC. : News, information and stories for PROTARA THERAPEUTICS, INC. | Nasdaq: TARA | Nasdaq Protara Therapeutics, Inc. 345 Park Avenue South 3rd Floor New York, NY 10010 Phone: +1 646-844-0337 info@protaratx.com. About Us; Pipeline; Careers; Investors NEW YORK, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced the appointment of Cynthia Smith to its Board of Directors. News zur PROTARA THERAPEUTICS AKTIE und aktueller Realtime-Aktienkurs Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 2021-04-19 · NEW YORK, April 19, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced the appointment of Martín Sebastian Olivo, M.D. as Chief Medical Officer, effective immediately. Protara Therapeutics (NASDAQ:TARA) priced its two concurrent but separate underwritten public offerings of 4.6M shares for $16.87/share and 4,148 shares of its non-voting Series 1 Protara Therapeutics, Inc. 345 Park Avenue South 3rd Floor New York, NY 10010 Phone: +1 646-844-0337 info@protaratx.com Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company’s lead p 2020-07-24 · NEW YORK, July 24, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing treatments for rare and specialty diseases with significant unmet needs Protara Therapeutics News .

The Protara Therapeutics , a clinical-stage pharmaceutical company, disclosed its path forward in the development of TARA-002, a therapy for treating lymphatic malformations in children. Relying on feedback from the U.S. Food and Drug Administration, the company plans to complete manufacturing comparability to a similar treatment in the second half Protara Therapeutics News Headlines $15.94 +0.32 (+2.05 %) (As of 03/10/2021 12:00 AM ET) Add. Compare. Share . Today's Range.